Modular Medical Announces Issuance Of U.S. Patent Covering Key Features Of Core Pumping Technology In FDA-Cleared MODD1 Insulin Delivery Product
Portfolio Pulse from Benzinga Newsdesk
Modular Medical has announced the issuance of a U.S. patent for key features of its core pumping technology in the FDA-cleared MODD1 insulin delivery product. This patent strengthens the company's intellectual property portfolio.
September 18, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Modular Medical has been granted a U.S. patent for its core pumping technology in the MODD1 insulin delivery product, which is already FDA-cleared. This development strengthens the company's intellectual property and could enhance its competitive position.
The issuance of a U.S. patent for the core pumping technology in the MODD1 product is a significant development for Modular Medical. It not only strengthens the company's intellectual property portfolio but also potentially enhances its competitive edge in the insulin delivery market. This could positively impact the company's stock price in the short term as it may lead to increased investor confidence and potential market opportunities.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100